Updated MDNA11 Clinical Trial Results in Advanced Solid Tumors Presented
“The most important message from today’s data is that they absolutely add to the differentiation of MDNA11’s mechanism relative to other next-generation IL-2s and reinforce the consistency of its anti-tumor activity in late stage cancers refractory to checkpoint inhibitors,” said Fahar Merchant, Ph.D., President and CEO of Medicenna. “With durable responses in multiple late stage metastatic tumors, including pancreatic, breast, colorectal, endometrial, bladder, anal cancer and melanoma, it is difficult for us not to conclude that MDNA11 demonstrates meaningful efficacy. The recent announcement of the NEO-CYT trial sponsored by Fondazione Melanoma, in pre-surgery patients with high-risk melanoma, provides external validation of our approach and adds to our conviction that MDNA11 is potentially a de-risked drug candidate for earlier stage cancer patients harbouring healthier immune systems. We look forward to sharing new and mature data in the coming weeks and months from the ABILITY-1 study, new data from the NEO-CYT study and non-human primate data with MDNA113, our targeted and conditionally activated anti-PD1-IL-2 BiSKIT which is anticipated to enter its first in human study later next year.”
Share:
More News
“These data underscore gotistobart’s potential to redefine treatment for patients with hard-to-treat squamous NSCLC whose disease has progressed after initial therapy and who face limited options,” said Prof. Özlem Türeci, M.D., Co-Founder and Chief Medical Officer at BioNTech. “In second- and later lines of treatment, the clinical relevance of novel
“The collaboration with Ratio represents an exciting opportunity to explore the potential of novel radiopharmaceutical approaches designed to address the complexity and heterogeneity of cancer,” said Ben Hickey, President of RayzeBio. “The combination of our respective technologies and complementary development expertise creates a strong foundation for generating a novel differentiated
“We believe these results mark a potentially important step forward in the treatment of EGFR exon 20 insertion mutation-positive non-small cell lung cancer,” said Fabio Benedetti, MD, Global Chief Medical Officer, Taiho Pharmaceutical. “To address the unmet medical needs of patients and their families, we will continue working closely with
“Recent clinical data validated KAT6 as a targetable mechanism in the treatment of HR+/HER2- breast cancer, including those with actionable mutations,” stated Charles Morris, MBChB, MRCP, Chief Medical Officer of Prelude. “Dual KAT6A/B inhibitors, however, demonstrated overlapping toxicities with current backbone therapies that may limit the utility in earlier lines